Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy

By Synnestvedt Marit  

Acta Oncologica, Vol. 52, Iss. 1, 2013-01 ,pp. : 91-101

Informa Healthcare

Access to resources Recommend Favorite

Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 14, Iss. 5, 2014-06 ,pp. : 639-645

Bentham Science Publishers

Access to resources Recommend Favorite

Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study

By Sawaki Masataka  

Breast Cancer, Vol. 19, Iss. 3, 2012-07 ,pp. : 253-258

Springer Publishing Company

Access to resources Recommend Favorite

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

By Lipton Allan   Goodman Laurie   Leitzel Kim   Cook Jennifer   Sperinde Jeff   Haddad Mojgan   Köstler Wolfgang   Huang Weidong   Weidler Jodi   Ali Suhail   Newton Alicia   Fuchs Eva-Marie   Paquet Agnes   Singer Christian   Horvat Reinhard   Jin Xueguang   Banerjee Joyee   Mukherjee Ali   Tan Yuping   Shi Yining   Chenna Ahmed   Larson Jeff   Lie Yolanda   Sherwood Thomas   Petropoulos Christos   Williams Stephen   Winslow John   Parry Gordon   Bates Michael  

Breast Cancer Research and Treatment, Vol. 141, Iss. 1, 2013-08 ,pp. : 43-53

Springer Publishing Company

Access to resources Recommend Favorite

Upregulation of HER-2/neu by Ovarian Ablation: Results of a Randomized Trial Comparing Leuprorelin to CMF as Adjuvant Therapy in Node-positive Breast Cancer Patients

By Lüftner D.  

Breast Cancer Research and Treatment, Vol. 80, Iss. 3, 2003-08 ,pp. : 245-255

Springer Publishing Company

Access to resources Recommend Favorite